Background:
Elicitors and symptoms of anaphylaxis are age dependent. However, little is known about typical features of anaphylaxis in patients aged 65 years or more.
Methods:
The data from the Network for Online Registration of Anaphylaxis (NORA) considering patients aged ≥65 (elderly) in comparison to data from adults (18–64 years) regarding elicitors, symptoms, comorbidities, and treatment measures were analyzed.
Results:
We identified 1,123 elderly anaphylactic patients. Insect venoms were the most frequent elicitor in this group (
p
< 0.001), followed by drugs like analgesics and antibiotics. Food allergens elicited less frequently anaphylaxis (
p
< 0.001). Skin symptoms occurred less frequently in elderly patients (77%,
p
< 0.001). The clinical symptoms were more severe in the elderly (51% experiencing grade III/IV reactions), in particular when skin symptoms (
p
< 0.001) were absent. Most strikingly, a loss of consciousness (33%,
p
< 0.001) and preexisting cardiovascular comorbidity (59%,
p
< 0.001) were more prevalent in the elderly. Finally, adrenaline was used in 30% of the elderly (vs. 26% in the comparator group,
p
< 0.001) and hospitalization was more often required (60 vs. 50%,
p
< 0.001).
Discussion and Conclusion:
Anaphylaxis in the elderly is often caused by insect venoms and drugs. These patients suffer more often from cardiovascular symptoms, receive more frequently adrenaline and require more often hospitalization. The data indicate that anaphylaxis in the elderly tends to be more frequently life threatening and patients require intensified medical intervention. The data support the need to recognize anaphylaxis in this patient group, which is prone to be at a higher risk for a fatal outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.